Predictors of Long-Term Visual Outcome in Intermediate Uveitis

• Published in: Ophthalmology (Rochester, Minn.) Vol. 124; no. 3; pp. 393 - 398
• Main Authors: Niederer, Rachael L., MBChB, PhD, Sharief, Lazha, MPH, MSc(Ophth), Bar, Asaf, MD, Lightman, Sue L., PhD, FRCOphth, Tomkins-Netzer, Oren, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2017
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Blindness - etiology; Blindness - physiopathology; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Glucocorticoids - therapeutic use; Humans; Infant; Male; Middle Aged; Ophthalmology; Risk Factors; Uveitis, Intermediate - complications; Uveitis, Intermediate - drug therapy; Uveitis, Intermediate - physiopathology; Vision, Low - etiology; Vision, Low - physiopathology; Visual Acuity - physiology; OCT; MVL; severe visual loss; optical coherence tomography; MS; multiple sclerosis; RPE; SVL; IQR; interquartile range; IU; logMAR; SUN; Standardization of Uveitis Nomenclature; BCVA; moderate visual loss; best-corrected visual acuity; CME; cystoid macular edema; retinal pigment epithelium; logarithm of the minimum angle of resolution; intermediate uveitis
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2016.11.013

Purpose To describe factors that predict visual loss and complications in intermediate uveitis. Design Cross-sectional study. Participants Subjects with intermediate uveitis were identified from a database of 1254 uveitis patients seen in the clinic of a single consultant (S.L.L.) between 2011 and 2013. Methods Information was gathered from the clinical notes of all subjects examined in clinic. Main Outcome Measures Best-corrected visual acuity (BCVA), moderate visual loss (MVL; ≤20/50), severe visual loss (SVL; ≤20/200). Results Three hundred and five subjects (550 eyes) were included in the study, comprising 24.3% of subjects seen in clinic. Mean (± standard deviation) age at diagnosis was 40.9±16.9 years, and 64.6% of subjects were female. Median follow-up was 8.2 years (mean, 9.7 years, 5452 eye-years). Systemic diagnosis was made in 36.1% of patients, with sarcoidosis (22.6%) and multiple sclerosis (4.6%) the most frequent systemic associations. Median BCVA was 20/30 (mean logarithm of the minimum angle of resolution [logMAR] 0.26±0.38, n = 550 eyes) at presentation, 20/30 (mean logMAR 0.22±0.42, n = 430) at 5 years, and 20/30 (mean logMAR 0.23±0.46, n = 260) at 10 years. Macular edema was observed in 224 eyes (40.7%) and was associated with idiopathic disease ( P  = 0.001) and diabetes ( P  = 0.001). Topical therapy was used in 82.7%, and 34.2% received local injections of corticosteroids. A total of 50.5% required oral steroids and 13.8% required second-line immunosuppression. Subjects with a diagnosis of sarcoidosis were less likely to require a second-line agent (4.3% vs. 16.2%, P  = 0.011). On multivariate analysis, visual acuity at referral, retinal pigment epithelial atrophy, and macular scarring were associated with increased risk of MVL; and visual acuity at referral, local therapy, macular scarring, retinal detachment, and hypotony and phthisis were associated with increased risk of SVL. Conclusions Intermediate uveitis has a long disease course with frequent complications and often requires systemic treatment. Despite this, most subjects are still able to achieve good long-term visual outcomes.